Highest-materiality recent filing
Anixa holds annual meeting; re-elects four directors, approves say-on-pay and auditor ratification
Re-elected Kumar, Baskies, Gottschalk, Titterton as directors; each received 7.2M+ votes for.
12 patients treated; 7 lived beyond expected median survival of 3-4 months; one survived 28 months.
Vaccine met all primary endpoints; 74% of participants showed protocol-defined aLA-specific T cell responses.
Anixa Biosciences annual meeting re-elects four directors, approves say-on-pay 66%-33%
Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, Lewis Titterton re-elected as directors with 97-99% of votes cast.
Phase 1 trial of alpha-lactalbumin vaccine updated at SITC; data continue positive trend across 3 cohorts.
Anixa expands Cleveland Clinic joint development to develop additional cancer vaccines
Anixa and Cleveland Clinic entered Joint Development and Option Agreement to develop vaccines for multiple cancers.
Anixa Biosciences re-elects four directors and ratifies auditor at 2024 annual meeting
Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. re-elected as directors with 7.9M-7.7M votes for.
Anixa reports positive Phase 1 breast cancer vaccine data; T-cell responses in 75% of patients
16 TNBC patients treated; 12/16 (75%) developed antigen-specific T-cell responses at all dose levels.
Anixa Biosciences and Cleveland Clinic report positive Phase 1 data for breast cancer vaccine
Phase 1 trial of triple-negative breast cancer vaccine showed antigen-specific T cell responses at all dose levels.
Anixa Biosciences stockholders re-elect four directors, approve say-on-pay, ratify auditor
Re-elected Dr. Amit Kumar (10.26M for, 940k withheld), Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton Jr.
Anixa Biosciences reaches maximum tolerated dose in Phase 1a trial of breast cancer vaccine
Maximum tolerated dose achieved in Phase 1a trial of preventative breast cancer vaccine.
Anixa Biosciences reports favorable safety and stable tumor lesions in first patient of CAR-T trial
First patient treated in chimeric endocrine receptor T-cell (CAR-T) clinical trial shows favorable safety signals.
Anixa Biosciences doses first patient in Phase 1 CAR-T trial for ovarian cancer
First patient dosed in Phase 1 trial of novel CER-T therapy for ovarian cancer at Moffitt Cancer Center.
Anixa promotes CFO/COO Michael Catelani to President; salary $434,512
Michael Catelani promoted to President effective April 14, 2022; retains roles as COO and CFO.
Re-elected directors Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. with between 8.4M and 9.2M votes for.
Anixa sets 2022 annual meeting for March 10; stockholder deadline Jan 10
2022 Annual Meeting of Stockholders scheduled for Thursday, March 10, 2022, held virtually on the internet.
Anixa corrects board member's misstatement: DoD grant for breast cancer vaccine is $6.2M
Dr. Arnold Baskies misspoke on NBC10 Philadelphia about the Department of Defense grant supporting the breast cancer vaccine.
Anixa Biosciences begins patient recruitment for Phase I breast cancer vaccine trial
Patient recruitment commenced Oct 1, 2021 for a preventative breast cancer vaccine developed with Cleveland Clinic and DoD.
On April 14, 2022, the Board of Directors of Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) promoted Michael Catelani, the current Chief Operating Officer and Chief Financial Officer of the Company, to President of the Company effective immediately.
Mr. Catelani is replacing Dr. Amit Kumar, the prior President and current Chairman and Chief Executive Officer of the Company.
Max materiality 0.80 · Median 0.53 · Most common event other_material